Updates to AIA HealthShield Gold Max for 1 October 2025 revisions

As the medical landscape continues to evolve, we remain committed to providing you access to quality healthcare. With this in mind, we are revising the AIA HealthShield Gold (HSG) Max policy benefits with effect from 1 October 2025, upon policy purchase or renewal.  

Summary of updates

We will be making the following changes to AIA HealthShield Gold Max (AIA HSG Max) plans and riders with effect from 1 October 2025 (new purchase and upon policy renewal):
 
Revisions AIA HSG Max A1 AIA HSG Max B1 AIA HSG Max B Lite
Outpatient and home-based treatments benefit NEW
Cell, tissue and gene therapy benefit2 REVISED
Limit per policy year REVISED No change No change
Pre-hospitalisation and post-hospitalisation benefits REVISED No change No change
Premium revisions 
Also applies to riders
(see below)
Also applies to rider
(see below)
No change
Revisions
AIA Max VitalHealth A / A Value & AIA Max VitalCare riders 
AIA Max VitalHealth B rider 
AIA Max VitalHealth B Lite rider 
Non-listed cell, tissue and gene therapy benefit NEW
Outpatient cancer care benefits REVISED No change
Home palliative care benefit EXTENDED No change Not covered
Premium revisions 
Only applies to AIA Max A Cancer Care Booster, AIA Max VitalHealth A and AIA Max VitalCare
No change
1 Also applies to AIA HSG Max Special A & B.
2 Will exclude any cell, tissue and gene therapy treatments that are not listed on the Cell, Tissue and Gene Therapy Product List.

(1) Changes to your AIA HSG Max to align with MediShield Life's (MSHL) changes

To align with MSHL changes, which the Ministry of Health of Singapore (MOH) has introduced in April 2025, we will be making the following changes to your AIA HSG Max (A/B/B Lite) policy: 
 
(a) Outpatient and home-based treatments benefit NEW  
Your policy will cover selected outpatient and home-based treatments and medical care provided in an outpatient setting or in your home at up to 2X the MSHL limits: 
 
Treatments  MSHL Limits HSG Max A HSG Max B HSG Max B Lite
Home ventilation and respiratory support service (HRVSS) 
S$840 per month 
S$1,680 per month
Negative pressure wound therapy (NPWT)  S$120 per day S$120 per day
Repetitive transcranial magnetic stimulation (rTMS)  S$120 per treatment session S$240 per treatment session
Pasteurised donated human milk (PDHM)  S$85 per day  S$85 per day
Hyperbaric oxygen therapy (HBOT) 
S$780 per treatment session
S$780 per treatment session
Outpatient parenteral antibiotic therapy (OPAT)  S$90 per day S$180 per day
 
This new benefit gives you access to more convenient care options beyond acute hospital setting. 
 
The insured does not need to be hospitalised for this benefit to apply. No deductible applies to the eligible expenses covered for this benefit, but you do have to pay co-insurance. 
 
(b) Cell, tissue and gene therapy treatment benefit REVISED  
 
Your policy will only cover clinically- and cost-effective cell, tissue and gene therapy treatments which are listed under the Cell, Tissue and Gene Therapy Product List (CTGTP treatment) developed by MOH.  
 
This benefit will only cover up to S$250,000 per indication per lifetime for each listed CTGTP treatment as shown in the schedule of benefits of the policy documents (Kymriah & Yescarta). 
 
(c) Coverage for high-cost drug treatments REVISED  
 
Your policy will only cover high-cost drug treatments used for the medical conditions indicated on the MSHL, which are assessed to be clinically- and cost-effective by MOH (listed on the MSHL's benefit schedule), under the current terms and conditions of your policy.  
 
(d) The following treatments will not be covered under your AIA HSG Max policy (including Standard, Max C & Plan 1 (FR) plans): 
  • Cell, tissue and gene therapy treatments that are not listed under the Cell, Tissue and Gene Therapy Product List (non-listed CTGTP treatments); and 
  • High-cost drugs treatments used for the medical conditions indicated under MSHL, which are not listed on the MSHL's benefit schedule. This website may be updated from time to time. 
 
If you have the following plans, there will be additional revision to your coverage: 
  • AIA HSG Max Plan 1 (FR) plan: All cell, tissue and gene therapy treatments will not be covered.  

(2) Added coverage for your AIA Max VitalHealth (A/B/B Lite) and AIA Max VitalCare riders.

(a) Non-listed cell, tissue and gene therapy benefit NEW
With the changes on cell, tissue and gene therapy on your basic plan, your rider will provide coverage for cell, tissue and gene therapy treatment not listed on the Cell, Tissue and Gene Therapy Product List (non-listed CTGTP treatments).  
 
The benefit will cover up to S$150,000 per indication per lifetime for each non-listed CTGTP treatment, subject to a co-insurance of 10% for every claim, without a co-payment and co-payment cap.  
 
(b) Increased coverage for 'Outpatient cancer care benefit' for AIA Max VitalHealth B and B Lite REVISED 
We will increase the limits under this benefit for outpatient cancer drug treatment and services to: 
 
  Before 1 Oct 2025 From 1 Oct 2025
Cancer drug treatment on the Cancer Drug List
10x MSHL limits
16x MSHL limits
Cancer drug services
8x MSHL limits
10x MSHL limits
Cancer drug treatment not on the Cancer Drug List
S$50,000 per policy year
S$100,000 per policy year
 
The adjusted limits will also apply to multiple primary cancers coverage as well. 

(3) Enhanced coverage to your AIA HSG Max B policy

(a) Limit per policy year for treatments under an AIA preferred provider REVISED
We will increase the limit per policy year up to S$1,200,000 for all hospitalisation (including outpatient treatments) provided by, or under, an AIA preferred provider within the same policy year.  
 
The annual limit of S$1,000,000 will continue to apply to all other claims. 
 
(b) Pre-hospitalisation and post-hospitalisation benefit for hospitalisation treatments under a public hospital REVISED
To encourage the usage of public hospitals, we will be extending the coverage period for hospitalisation treatment under a public hospital: 
 
Type of hospitalisation treatment  Before 1 Oct 2025 From 1 Oct 2025
Pre-hospitalisation benefit 
Within 180 days before hospitalisation  
(applies to all hospitals)
Public hospital: Within 12 months before hospitalisation
Private hospital: Within 100 days before hospitalisation
Post-hospitalisation benefit (Post-hospitalisation treatment)
Within 180 days after hospitalisation (applies to all hospitals)
Public hospital: Within 12 months after hospitalisation
Private hospital: Within 100 days after hospitalisation
 
The coverage for treatments under a private hospital will also be revised as shown above. 
 
(c) Introducing 'Home palliative care benefit' to AIA Max VitalHealth B rider : 
To provide support for terminally ill patients who need to receive care in the comfort of their home, we will be introducing 'Home palliative care benefit' to AIA Max VitalHealth B rider, up to S$10,000 per month, with a lifetime limit of S$30,000. 

(4) Premium revision to AIA HSG Max A & B and its riders

We will be revising the premium rates from 1 October 2025 to the following plans and riders: 
  • AIA HSG Max A (or Special A) 
    • AIA Max VitalHealth A 
    • AIA Max VitalCare 
    • AIA Max A Cancer Care Booster 
  • AIA HSG Max B (or Special B) 
    • AIA Max VitalHealth B
The revised premium rates reflect the increase in healthcare cost and claims arising from advancement in medical technologies, medical inflation and changes to the medical landscape. 
 
For existing customers, the revised premium rates will apply on the policy anniversary from 1 October 2025. 
 
There is no change to the premium rates for AIA Max VitalHealth A Value and Emergency and Outpatient Care Booster. 
 
Please refer to the FAQ for more information.

Have a question about the changes?

We have compiled a list of FAQs to help you get the information you need.

Recommendation Prompt